Adaptive Biotechnologies Corp (ADPT) Unusual Options Activity Today

Checking ADPT unusual options activity helps you spot when traders are making outsized bets on Adaptive Biotechnologies Corp before the broader market catches on. Adaptive Biotechnologies Corp's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor ADPT unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching ADPT unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking ADPT unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and ADPT unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines.

In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Catalysts rarely arrive without a footprint, and ADPT unusual options activity is often where that footprint shows up first. Our scanner tracks Adaptive Biotechnologies Corp's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at ADPT unusual options volume on the call side or chasing put sweeps, Adaptive Biotechnologies Corp's unusual options flow today is one click away, so put it on your radar before the headlines hit.